1. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors
- Author
-
Mark A. Wainberg, Ying-Shan Han, and Thibault Mesplède
- Subjects
0301 basic medicine ,Microbiology (medical) ,Pyridones ,030106 microbiology ,Integrase inhibitor ,HIV Infections ,Drug resistance ,Quinolones ,Biology ,Microbiology ,Piperazines ,Raltegravir Potassium ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Resistance, Viral ,Oxazines ,Genetics ,medicine ,Humans ,HIV Integrase Inhibitors ,Molecular Biology ,Ecology, Evolution, Behavior and Systematics ,Elvitegravir ,Raltegravir ,Virology ,Integrase ,Infectious Diseases ,chemistry ,Dolutegravir ,HIV-1 ,biology.protein ,Heterocyclic Compounds, 3-Ring ,medicine.drug ,Hiv subtypes - Abstract
Three integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), have been approved by the FDA. Resistance against these three INSTIs have been reported and cross-resistance among them has been documented. Due to extensive and dynamic genetic diversity in different HIV-1 variants, significant differences in susceptibility to the INSTIs have been observed among HIV subtypes. This review summarizes what is known about this topic and discusses possible clinical implications.
- Published
- 2016
- Full Text
- View/download PDF